Amyloid-Binding Peptoids for Alzheimer's Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease, particularly sporadic forms, are ineffective in preventing or reversing the condition, with existing therapies failing to address the root causes and often causing neuroinflammation due to the complex immunomodulatory effects and proteolytic vulnerability of LL-37 peptides, while also struggling to effectively cross the blood-brain barrier.
Innovation Solution
Development of peptoid mimics, such as Peptoid 1, which are resistant to proteolysis and can cross the blood-brain barrier with the aid of BBB manipulators like docosahexaenoic acid and nanocarriers, to inhibit Aβ amyloid formation and have broad-spectrum antimicrobial activity, thereby targeting toxic Aβ oligomers and associated pathogens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If LL-37 peptides are used to treat Alzheimer's disease, then amyloid formation may be inhibited, but the peptides are vulnerable to proteolysis and cause neuroinflammation
Solution Approach 1:
The patent creates peptoid copies that mimic the structure and function of LL-37 peptides. These peptoid mimics replicate the amyloid-inhibiting and antimicrobial properties of LL-37 while being resistant to proteolytic degradation, thus resolving the contradiction between therapeutic effectiveness and proteolytic stability
Solution Approach 2:
The invention combines peptoid structures with blood-brain barrier manipulators to create composite therapeutic agents. This composite approach enables the peptoids to cross the BBB effectively while maintaining their stability and therapeutic function, addressing both the stability and effectiveness requirements
2Reliability
If LL-37 peptides are used to treat Alzheimer's disease, then amyloid formation may be inhibited, but neuroinflammation is caused due to complex immunomodulatory effects
Solution Approach 1:
The peptoid mimics copy the beneficial amyloid-inhibiting function of LL-37 without replicating its harmful immunomodulatory effects. This selective copying allows the peptoids to inhibit amyloid formation and kill pathogens while avoiding the neuroinflammation caused by native LL-37
Solution Approach 2:
The invention extracts and isolates the beneficial functions of LL-37 (amyloid inhibition and antimicrobial activity) while leaving behind the harmful immunomodulatory effects. The peptoids are designed to perform only the desirable functions without causing neuroinflammation
3Stability of the object's composition
If peptoids are designed to be stable and effective, then they resist proteolysis, but they struggle to cross the blood-brain barrier
Solution Approach 1:
The patent introduces blood-brain barrier manipulators as intermediary agents that facilitate the transport of stable peptoids across the BBB. These manipulators act as carriers or enhancers that enable the peptoids to cross the barrier without compromising their stability or therapeutic function
Solution Approach 2:
The invention creates composite formulations combining peptoids with BBB-penetrating agents. This composite approach allows the stable peptoids to be delivered effectively into the brain by leveraging the barrier-crossing capabilities of the accompanying manipulators
4Ease of manufacture
If existing therapies are used for Alzheimer's disease, then treatment is provided, but they fail to address root causes and are ineffective in preventing or reversing the condition
Solution Approach 1:
The peptoid mimics copy the structure and function of natural host-defense peptides like LL-37, which are involved in clearing amyloid and fighting infections. By replicating these natural protective mechanisms, the peptoids address the root causes of Alzheimer's (amyloid accumulation and pathogen burden) that existing therapies fail to target
Solution Approach 2:
The peptoids possess multiple functions: they inhibit amyloid formation, kill bacteria, viruses, and fungi, and cross the blood-brain barrier. This multi-functionality allows a single therapy to address multiple root causes of Alzheimer's simultaneously, overcoming the limitations of existing single-function treatments
Data Source
AI summary
A method is provided for treating a subject suffering from a chronic infection that involves the brain. The chronic infection may range from those causing only mild cognitive impairment, to those present in individuals who have been diagnosed with Alzheimer's Disease. The method includes forming a composition containing (a) an anti-infective peptoid, and (b) a blood-brain barrier (BBB) manipulator that enhances the ability of the anti-infective peptoid to cross the BBB; and administering a therapeutic amount of the composition to a subject in need thereof.